ABOUT

Responding to the ongoing epidemic COVID-19 coronavirus outbreak, the FASTCURE consortium aims to rapidly identify, collect and verify chemical compounds and methods suitable for inhibiting SARS-CoV-2 (formerly known as 2019-nCoV) Mpro protease as a primary target. World-wide leading institutions active in bioinformatics, drug- screening and design supported by major European HPC facilities will be redundantly cross-linked with high-throughput experimental in-vitro and in-vivo validation methods comprising cell culture compound screening, X-ray and NMR complex determination to continuously evaluate potential compounds. The compounds we suggest will be verified and classified in terms of previously approved (repurposed), experimental and “novel” by our bioinformatics, cheminformatics, structural biological, pharmaceutical and medical advisory boards and all data produced will be open-access. Authorities, WHO and CDC will be immediately notified of the findings and dissemination of our findings to other consortia is implemented right from the start. The project is designed to permanently stay open to outside input contributed by any 3rd party. We will continuously screen all published data and integrate findings such as newly emerging, potentially evolved genomes, structural, medical and biochemical data. In the formation of the consortium, complementarity was stressed, however, we have ensured sufficient redundancy to be able to continue the project in case of an unexpected loss of personnel, computer or other resources, thereby also improving our chances of success. Dissemination is guaranteed by attached industrial partners with expertise in taking anti-viral substances all the way to market launch. The lessons-learned, the DMS and automised work-flows, from the genome to the drug candidates will be made available as a cloud-based, distributed global emergency response system to ensure an immediate and well-coordinated response to future outbreaks.

Contact us anytime at contributions@fastcure.net.

PARTNERS

Academic Partners

University of Graz

Institute of Molecular Biosciences, Structural biology and crystallography

Institut of Chemistry, Enzymology and biocatalysts

Medical University of Graz

Molecular Biology and Biochemistry, Bio-NMR

Infectiology and tropical medicine, University of Graz

University of Oxford

Structural Genomics Consortium

Medical University of Vienna

Department of Medicine, Division of Infectious Diseases and Tropical Medicine

Universidad Católica San Antonio de Murcia

Structural Bioinformatics and High Performance Computing Research Group

University of Innsbruck

Institute of Biochemistry, epidemic novel pathogens antibody response

Harvard Medical School

Biological Chemistry and Molecular Pharmacology

Helmholtz Centre for Infection Research

COPS (Compound Profiling and Screening)

ShanghaiTech

Lab of Infection and Anti-infection, Shanghai Institute for Advanced

National Institute for Infectious Diseases „L. Spallanzani“

Laboratory of Virology

Dana-Farber Cancer Institute

French National Centre for Scientific Research

Diamond Light Source

PARTNERS

Company Partners

Modelling and structural bioinformatics, Catalophore Drug Discovery

High-throughput mining of structural data

Acib, Austrian centre of industrial biotechnology

Adjuvatis

PARTNERS

Computational Resources & Technical Support

Innophore GmbH computing facilities and University of Graz

Vienna Science Cluster

provided by European Commission

Graz University of Technology

Institute of Interactive Systems and Data Science, DMS CyVerse

Primary Target

SARS-CoV-2 main protease Mpro

GLOBAL NETWORK

Consortium map